Oshi Health, a digital gastrointestinal health company, announced that it had garnered $30 million in Series B funding. 

Koch Disruptive Technologies (KDT) led the round, with participation from existing investors Flare Capital Partners, Bessemer Venture Partners, CVS Health Ventures, Frist Cressey Ventures and Takeda Digital Ventures.

WHAT IT DOES

Oshi provides patients with gastrointestinal issues virtual access to a team of providers, including a gastroenterologist, behavioral health clinician, dietitian and health coach. The company offers support for digestive concerns such as Crohn's Disease, irritable bowel syndrome (IBS) and ulcerative colitis. Patients can also utilize the company's symptom tracking tool and instant message with their providers. 

The New York-based company will use the funds to add to its clinical team in the U.S. and expand its reach with employers, provider groups, health plans and channel partners. 

"We've seen the impact of Oshi Health's unique care model, and we want to be part of helping health plans and employers understand the significant potential of its virtual multidisciplinary digestive care," David Mauney, managing director of Koch Disruptive Technologies, said in a statement. "We are excited to help scale access to Oshi's best-in-class virtual clinic and proven outcomes which have given them the clear market lead."

MARKET SNAPSHOT

Last week, Aetna, the insurer owned by CVS Health, announced a value-based care partnership with Oshi, which would allow commercial members in Florida, Maine, Massachusetts, Ohio, Pennsylvania and Texas with select Aetna plans to access Oshi as an in-network provider.  

In 2022, virtual care company Firefly Health announced a partnership with Oshi to offer digital digestive care to its members. Solera Health, a digital platform offering a marketplace for benefits and chronic disease management programs, also announced that it would offer gastrointestinal-focused digital health products from Oshi.

In 2021, Oshi Health garnered $23 million in Series A funding.

Dr. Tufia Haddad, Becky Kottschade and Rebecca Heft will offer more detail in the HIMSS23 session "Decentralized Clinical Trials Implementation Approach." It is scheduled for Wednesday, April 19, at 10 a.m. – 11 a.m. CT at the South Building, Level 5, room S501.